{"nctId":"NCT00562861","briefTitle":"Treatment for Bipolar Depression: Acute & Prophylactic Efficacy With Citalopram","startDateStruct":{"date":"2007-11"},"conditions":["Bipolar Disorder","Bipolar Depression"],"count":119,"armGroups":[{"label":"citalopram + mood stabilizer","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: citalopram + mood stabilizer"]},{"label":"placebo + mood stabilizer","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: placebo + mood stabilizer"]}],"interventions":[{"name":"citalopram + mood stabilizer","otherNames":["Celexa"]},{"name":"placebo + mood stabilizer","otherNames":["lithium, lamotrigine, valproate, or carbamazepine"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Current age ≥18 years\n* DSM-IV diagnosis of BPD, type-I, or type-II\n* Current major depressive episode using DSM-IV criteria, lasting 8 weeks or longer.\n* Use of lithium, divalproex, carbamazepine, or lamotrigine at therapeutic serum levels or doses for ≥4 weeks prior to study entry, or willingness to accept one of these agents.\n* Prior to initial evaluations, each subject must provide competent, written, informed consent.\n\nExclusion Criteria:\n\n* Past non-response to a therapeutic trial of R,S-citalopram (≥100 mg/day for ≥8 weeks).\n* Previous intolerance of R,S-citalopram;\n* Diagnosis of unipolar depression\n* Diagnosis of schizoaffective disorder\n* Serious medical illness with acute instability (cardiac, respiratory, hepatic, renal), based on hospitalization in the past month\n* Abnormal thyroid function tests\n* Previous allergic reaction to or inability to tolerate lithium, divalproex, or carbamazepine at therapeutic serum levels.\n* Current or past renal dysfunction if taking lithium\n* Current or past hepatitis or other liver disease if taking divalproex\n* Current or past hematologic disease if on carbamazepine\n* Severe suicidal ideation, plan or intent, as documented by a score of ≥4 on the Montgomery Åsberg Depression Rating Scale suicidality item (Item 10).\n* Presence of psychosis\n* Cognitive impairment sufficient to impair ability to give informed consent.\n* Current pregnancy, or inability to utilize contraception\n* The presence of any metallic implants\n* History of claustrophobia","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"64 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"MADRS Rating Scale Change","description":"Montgomery Asberg Depression Rating scale assessed in mixed effects regression model. The total range for the scale is 0 to 60. Lower values involve less depression, while higher values involve worse depression. The change in the MADRS scale is interpreted as higher values meaning better outcomes, because more depressive symptoms are improved.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.1","spread":"8.4"},{"groupId":"OG001","value":"15.2","spread":"9.9"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":60},"commonTop":["sedation","headache","nausea","dry mouth","diarrhea"]}}}